Karachalios G N
Int J Clin Pharmacol Ther Toxicol. 1985 Dec;23(12):647-9.
Forty-four patients with respiratory tract infections were treated using a new formulation of amoxycillin and clavulanic acid. Clinical diagnosis was classified as follows: 19 cases of acute exacerbations of chronic bronchitis, 10 cases of bronchiectasis, and 15 cases of diffuse or localized pneumonia. Amoxycillin/clavulanic acid combination (amoxycillin 250 mg + clavulanic acid 125 mg per tablet) was administered as 2 tablets three times per day for 7-14 days. The efficacy was as follows: chronic bronchitis 94.7%, bronchiectasis 80.0% and pneumonia 93.3%. No severe adverse reactions occurred in treated patients and no renal, hepatic or hematological toxicity was observed. Amoxycillin/clavulanic acid combination was a safe and effective antimicrobial agent for the treatment of respiratory tract infections.
44例呼吸道感染患者采用一种新配方的阿莫西林和克拉维酸进行治疗。临床诊断分类如下:慢性支气管炎急性加重19例,支气管扩张10例,弥漫性或局限性肺炎15例。阿莫西林/克拉维酸组合(每片含阿莫西林250毫克 + 克拉维酸125毫克),每日3次,每次2片,服用7 - 14天。疗效如下:慢性支气管炎为94.7%,支气管扩张为80.0%,肺炎为93.3%。治疗患者未发生严重不良反应,未观察到肾、肝或血液学毒性。阿莫西林/克拉维酸组合是治疗呼吸道感染的一种安全有效的抗菌药物。